Press Releases Year None2022202120202019201820172016 Apr 05, 2022 Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia Mar 15, 2022 Imara Reports Full Year 2021 Financial Results and Business Highlights Mar 08, 2022 Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights Feb 10, 2022 Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference Jan 25, 2022 Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF) Jan 05, 2022 Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Press Releases Year None2022202120202019201820172016 Apr 05, 2022 Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia Mar 15, 2022 Imara Reports Full Year 2021 Financial Results and Business Highlights Mar 08, 2022 Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights Feb 10, 2022 Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference Jan 25, 2022 Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF) Jan 05, 2022 Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
Apr 05, 2022 Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
Mar 08, 2022 Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
Jan 25, 2022 Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
